Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Regulatory Update: Mepolizumab For The Treatment Of Hypereosinophilic Syndrome (HES)
GSK announced that it has notified the European Medicines Agency of its decision to withdraw the Marketing Authorisation Application (MAA) in the EU for mepolizumab for the treatment of hypereosinophilic syndrome (HES).
generic viagra online
Cellceutix Files Patent Application For Its Cancer Compound
Cellceutix Corporation (OTCBB: CTIX), announced it has filed a U.S. patent application covering pharmaceutical formulations of a compound referred to as Kevetrin™ and many novel compounds having similar structures to Kevetrin. These structures cover a large number of compounds that Cellceutix can look at as possible drug development candidates. The application covers the use of Kevetrin™ and the other compounds in various areas, including cancers. Cellceutix plans to file in other countries within a year of the U.S. filing.
News of the day
FDA Approves First Canine Cancer Therapy
Pfizer Animal Health today announced that the U.S. Food and Drug Administration (FDA) has approved the first canine cancer therapy in the U.S. - PALLADIATM (toceranib phosphate) - which was developed by Pfizer to treat mast cell tumors in dogs. Pfizer made the announcement to veterinarians attending the 2009 American College of Veterinary Internal Medicine (ACVIM) Forum and Canadian Veterinary Medical Association Convention.
Public Health

International Stem Cell Corporation Reports Positive Pre-Clinical Trial Results From Human Corneal Epithelial Cells

International Stem Cell Corporation (OTCBB:ISCO), the first company to perfect a method of creating human "parthenogenetic" stem cells from unfertilized eggs, has received positive early results from animal trials designed to improve photorefractive keratectomy (PRK), a form of corrective laser eye surgery that offers an improved alternative to LASIK. PRK is generally thought to be safer and produce better long-term results than LASIK, but has not been used as frequently because of patient discomfort following surgery and a longer healing time. By combining ISCO"s human corneal cells with a proprietary surgical device developed by Paul H. Chen, M.D., who is conducting the trials, ISCO and Dr. Chen believe that cellular enhanced PRK can replace LASIK for many of the hundreds of thousands of patients who now use LASIK. The first stage animal trials just completed demonstrated that ISCO"s corneal cells manufactured by ISCO"s subsidiary, Lifeline Cell Technology, encouraged corneal-defect healing in the animals. The trials are the first step toward gaining Food and Drug Administration (FDA) approval to test the efficacy of using ISCO"s cells to improve healing after corneal surgery, and could result in the first FDA approved use of human cells produced by ISCO. Jeffrey Janus, President of ISCO and CEO of Lifeline, noted that "The cells used in these trials are derived from donated human tissue processed using proprietary techniques devised by ISCO"s subsidiary, Lifeline Cell Technology. However, ISCO"s parthenogenic stem cells can also produce human corneal cells. Corneal cells derived from ISCO"s parthenogenetic stem cells may provide a consistent and reliable of corneal cells that could eliminate entirely the need for donated human tissues." This work is being done in collaboration with Dr. Chen, who has developed the cell transfer technology. Dr. Chen is an eye surgeon at North County Laser Eye Associates, and he is on staff at Scripps Memorial La Jolla and Scripps Encinitas Hospitals. For more news and information on International Stem Cell Corporation please visit http://www.IRGnews.com/coi/ISCO where you can find the CEO"s video, a fact sheet on the company, investor presentations, and more. International Stem Cell Corporation (ISCO.OB)


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009